Atlas Trials

Study to Evaluate the Efficacy and Safety of SHR6390 Combined With Pyrotinib in HER2+ Advanced Breast Cancer

Clinical trial NCT04293276 · UNKNOWN

Trial details

NCT number
NCT04293276
Sponsor
Henan Cancer Hospital
Status
UNKNOWN
Phase
Phase 2
Study type
INTERVENTIONAL
Metastatic Breast Cancer
Start date
2020-04-01
Primary completion
2021-08-23
Enrollment
41

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.